<DOC>
	<DOCNO>NCT01297192</DOCNO>
	<brief_summary>This study investigate whether mirabegron ( YM178 ) effect pharmacokinetics solifenacin whether solifenacin effect pharmacokinetics mirabegron .</brief_summary>
	<brief_title>A Clinical Study Assess Effect Pharmacokinetics Dosing Mirabegron ( YM178 ) Solifenacin Simultaneously</brief_title>
	<detailed_description />
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Mirabegron</mesh_term>
	<criteria>Male subject must agree sexual abstinence and/or use highly effective method birth control screen 3 month last dose study medication Female subject must nonchild bear potential , i.e . post menopausal , surgically sterilize ( e.g . tubal ligation ) , hysterectomy medical history , must practice adequate nonhormonal contraceptive method prevent pregnancy . Nonhormonal contraceptive method define : sexual abstinence 1 month admission 3 month discharge subject 's sexual partner surgically sterilize ( since least 3 month prior screen ) , subject two ( 2 ) follow contraceptive method : I. diaphragm spermicide II . intrauterine device III . sexual partner use condom combination spermicidal cream Body Mass Index 18.5 30.0 kg/m2 , inclusive Known suspect hypersensitivity mirabegron component formulation use Known suspect hypersensitivity solifenacin succinate component formulation use Pregnant breast feeding within 6 month screen assessment . Any liver function test ( i.e . ALT , AST Alkaline phosphatase ) upper limit normal repeated measure Any clinical significant history risk urinary retention , severe gastrointestinal condition ( include toxic megacolon ) , myasthenia gravis narrowangle glaucoma Any clinically significant history asthma , eczema , clinically significant allergic condition previous severe hypersensitivity drug ( exclude nonactive hay fever ) Any clinically significant history disease disorder gastrointestinal , cardiovascular , respiratory , renal , hepatic , neurological , dermatological , psychiatric metabolic judge medical investigator Any clinically significant abnormality follow investigator 's review prestudy physical examination , ECG clinical laboratory test Abnormal pulse and/or blood pressure measurement prestudy visit follow : pulse &lt; 40 &gt; 90 bpm ; mean systolic blood pressure &gt; 140 mmHg ; mean diastolic blood pressure &gt; 90 mmHg ( blood pressure measurement take triplicate subject rest supine position 5 min ; pulse measure automatically ) A marked baseline prolongation QT/QTc interval repeat measurement &gt; 450 m , history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia torsades de pointes , structural heart disease , family history Long QT syndrome ( LQTS ) Use prescribed OTC ( overthe counter ) drug ( include vitamin , oral contraceptive hormone replacement therapy , natural herbal remedy , e.g . St. John 's wort ) 2 week prior admission Clinical Unit , except paracetamol ( 3 g/day ) Regular use inducer liver metabolism ( e.g . barbiturate , rifampin ) 3 month prior admission Clinical Unit Any use drug abuse within 3 month prior admission Clinical Unit History smoke 10 cigarette ( equivalent amount tobacco ) per day within 3 month prior admission Clinical Unit History drink 21 unit alcohol per week ( 1 unit=270 cc beer 40 cc spirit 1 glass wine ) ( &gt; 14 unit alcohol female subject ) within 3 month prior admission Clinical Unit Donation blood blood product within 3 month prior admission Clinical Unit Positive serology test HBsAg , anti HAV ( IgM ) , antiHCV antiHIV 1+2 Subject , opinion investigator , likely complete trial reason Participation clinical study within 3 month participation 3 clinical study within 12 month , prior expect date enrolment study , provide clinical study entail biological compound long terminal half life Any clinical condition , , opinion investigator , would allow safe completion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>YM178</keyword>
	<keyword>Mirabegron</keyword>
	<keyword>DDI</keyword>
	<keyword>Phase I</keyword>
	<keyword>Solifenacin</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacokinetics mirabegron</keyword>
</DOC>